Protein Engineering and Homologous Expression of Serratia Marcescens Lipase for Efficient Synthesis of a Pharmaceutically Relevant Chiral Epoxyester.
Ke-Cai Chen,Ming-Min Zheng,Jiang Pan,Chun-Xiu Li,Jian-He Xu
DOI: https://doi.org/10.1007/s12010-017-2543-z
2017-01-01
Applied Biochemistry and Biotechnology
Abstract:The lipase isolated from Serratia marcescens (LipA) is a useful biocatalyst for kinetic resolution of a pharmaceutically relevant epoxyester, (±)-3-(4′-methoxyphenyl) glycidic acid methyl ester [(±)-MPGM], to afford optically pure (−)-MPGM, a key intermediate for the synthesis of diltiazem hydrochloride. Two mutants, LipA L315S and LipA S271F , were identified from the combinatorial saturation mutation library of 14 amino acid residues lining the substrate-binding pocket. LipA L315S , LipA S271F , and their combination LipA L315S/S271F showed 2.6-, 2.2-, and 4.6-fold improvements in their specific activities towards para -nitrophenyl butyrate ( p NPB), respectively. Among these positive mutants, LipA S271F displayed a 3.5-fold higher specific activity towards the pharmaco substrate (±)-MPGM. Kinetic study showed that the improvement in catalytic efficiency of LipA S271F against (±)-MPGM was mainly resulted from the enhanced affinity between substrate and enzyme, as indicated by the decrease of K m . Furthermore, to address the insoluble expression issue in Escherichia coli , the homologous expression of LipA gene in S . marcescens was achieved by introducing it into an expression vector pUC18, resulting in ca . 20-fold higher lipase production. The significantly improved volumeric production and specific activity of S . marcescens lipase make it very attractive as a new-generation biocatalyst for more efficient and economical manufacturing of (−)-MPGM.